Currentculinary health fundPolicy N/A

Hemophilia — Factor VIII Products Utilization Management Medical Policy

This policy governs prior authorization and coverage criteria for recombinant and plasma-derived Factor VIII products (including extended half-life and standard products) for management of Hemophilia A and certain von Willebrand disease indications for Culinary Health Fund members.

Policy Summary

Payerculinary health fund

PolicyHemophilia — Factor VIII Products Utilization Management Medical Policy

Policy CodePolicy N/A

Change TypeNo material change

Effective Date

Next Review DateFeb 28, 2026

Key ActionObtain prior authorization and ensure the agent is prescribed by or in consultation with a hemophilia specialist; approve for one year if criteria met.

SourceLink

POLICY UPDATE CHANGES

No material clinical or coverage changes in this revision.

16listed Factor VIII products subject to prior authorization

1 yearstandard approval duration

up to 200 IU/kgmax immune tolerance dosing

variesroutine prophylaxis dosing ranges

Recommended Authorization Criteria

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Initial therapy — listed recombinant and standard half-life products

Coverage of Adynovate, Eloctate, Esperoct, Jivi, Advate, Afstyla, Kogenate FS, Kovaltry, Novoeight, Nuwiq, Recombinate, and Xyntha is recommended in those who meet the following criteria.

FDA-Approved Indication for listed products

Dosing options for Adynovate/Eloctate/Esperoct/Jivi: i. Routine prophylaxis: approve up to 100 IU per kg IV no more frequently than twice weekly; OR ii. On-demand treatment and control of bleeding episodes: approve up to 65 IU per kg IV no more frequently than once every 8 hours for up to 10 days per episode; OR iii. Perioperative management: approve up to 65 IU per kg IV no more frequently than once every 6 hours for up to 10 days per procedure; OR iv. Immune tolerance therapy (immune tolerance induction): approve up to 200 IU per kg IV once daily.
Dosing options for Advate/Afstyla/Kogenate FS/Kovaltry/Novoeight/Nuwiq/Recombinate/Xyntha: i. Routine prophylaxis: approve up to 60 IU per kg IV no more frequently than every other day (three or four times weekly); OR ii. On-demand treatment and control of bleeding episodes: approve up to 50 IU per kg IV no more frequently than once every 6 hours for up to 10 days per episode; OR iii. Perioperative management: approve up to 60 IU per kg IV no more frequently than once every 6 hours for up to 10 days per procedure; OR iv. Immune tolerance therapy (immune tolerance induction): approve up to 200 IU per kg IV once daily.

Initial therapy — Hemofil M and Koate

Coverage of Hemofil M and Koate is recommended in those who meet the following criteria.

FDA-Approved Indication for Hemofil M and Koate

Dosing: A) Routine prophylaxis: approve up to 50 IU per kg IV no more frequently than every other day (three or four times weekly); OR B) On-demand treatment and control of bleeding episodes and perioperative management: approve up to 50 IU per kg IV no more frequently than once every 6 hours for up to 10 days per episode or procedure; OR C) Immune tolerance therapy (immune tolerance induction): approve up to 200 IU per kg IV once daily.

Initial therapy — Alphanate, Humate-P, Wilate (Hemophilia A and VWD)

Coverage of Alphanate, Humate-P, and Wilate is recommended in those who meet one of the following criteria:

Hemophilia A indication: Patient has Hemophilia A; agent prescribed by or in consultation with a hemophilia specialist; approve for 1 year. Dosing: A) Routine prophylaxis: approve up to 50 IU per kg IV no more frequently than every other day (three or four times weekly); OR B) On-demand treatment and control of bleeding episodes and perioperative management: approve up to 50 IU per kg IV no more frequently than once every 6 hours for up to 10 days per episode or procedure; OR C) Immune tolerance therapy (immune tolerance induction): approve up to 200 IU per kg IV once daily.

Von Willebrand Disease indication: Patient has Von Willebrand Disease; agent prescribed by or in consultation with a hemophilia specialist; approve for 1 year. Dosing: A) On-demand treatment and control of bleeding episodes and perioperative management: approve up to 80 IU VWF:RCo per kg IV no more frequently than once every 8 hours for up to 10 days per episode or procedure; OR B) Routine prophylaxis: approve up to 40 IU VWF:RCo per kg IV no more frequently than once every 2 days.

Coverage of the Factor VIII products cited in this policy is limited to the circumstances described in the Recommended Authorization Criteria. Requests for use outside those specified indications, dosing regimens, or patient populations are not recommended for approval and may be denied; the criteria will be updated as new published data become available.

Dosing and Coding Thresholds

Dosing thresholds — routine prophylaxis and on‑demand/perioperative dosing specified per product

EHL products (Adynovate, Eloctate, Esperoct, Jivi) — routine prophylaxisApprove up to 100 IU/kg IV no more frequently than twice weekly.

EHL products — on‑demand/perioperativeApprove up to 65 IU/kg IV no more frequently than once every 8 hours (on‑demand) or once every 6 hours (perioperative) for up to 10 days per episode/procedure.

Standard/recombinant SHL products (Advate, Afstyla, Kogenate FS, Kovaltry, Novoeight, Nuwiq, Recombinate, Xyntha) — routine prophylaxisApprove up to 60 IU/kg IV no more frequently than every other day (3–4 times weekly).

Standard/recombinant SHL products — on‑demand/perioperativeApprove up to 50 IU/kg IV no more frequently than once every 6 hours for up to 10 days per episode or procedure.

Immune tolerance therapy (all listed Factor VIII products)Approve up to 200 IU/kg IV no more frequently than once daily.

Prescriber and Authorization Requirements

Prior Authorization

Prior Authorization Required — Factor VIII Products

Prior Authorization is recommended for medical benefit coverage of listed Factor VIII products. Approval is recommended for members who meet the policy Criteria and Dosing for the listed indications. Requests for doses outside the established dosing documented in this policy will be considered on a case-by-case basis by a clinician (Medical Director or Pharmacist).

Prior authorization required for Adynovate, Eloctate, Esperoct, Jivi, Advate, Afstyla, Kogenate FS, Kovaltry, Novoeight, Nuwiq, Recombinate, Xyntha, Hemofil M, Alphanate, Humate-P, Koate, Wilate
Dose exceptions reviewed individually by clinician (Medical Director or Pharmacist)
Approvals provided for the duration noted in the policy; extended approvals allowed if criteria continue to be met

Documentation Required

Prescriber Specialty Requirement

Because of the specialized skills required for evaluation, diagnosis, and monitoring of patients receiving recombinant Factor VIII products, the agent must be prescribed by or in consultation with a physician who specializes in the condition being treated.

Prescriber must be a relevant specialist or in documented consultation with a specialist
Documentation of specialist involvement should be provided with the authorization request

Documentation Required

Dose Exceptions Handled Case-by-Case

Requests for dosing outside the established dosing in this policy are not automatically approved and will be evaluated on an individual basis. A clinician (Medical Director or Pharmacist) will review clinical justification and relevant records to determine approval.

Provide clinical rationale and supporting documentation for dose exceptions (e.g., weight changes, bleeding history, inhibitor status, pharmacokinetic data)
Dose-exception decisions documented in the member's file; approvals may be time-limited

Denial Risk

Non-Listed Indications — Denial Risk

Coverage of the cited Factor VIII products is not recommended for indications outside those listed in the Recommended Authorization Criteria. Requests for non-listed indications carry a risk of denial.

Requests for indications not specified in the policy are likely to be denied
If new published data support additional indications, criteria will be updated

Key Definitions

Hemophilia A definition and severity classification

DefinitionHemophilia A is an X‑linked bleeding disorder caused by deficiency of Factor VIII, leading to bleeding episodes in joints, muscles, CNS and other sites.

Severity classification — MildFactor VIII activity 6% to 49% of normal.

Severity classification — ModerateFactor VIII activity 1% to 5% of normal.

Severity classification — SevereFactor VIII activity < 1% of normal; approximately 60% of patients are classified as severe.

VWD (von Willebrand disease) definition and types

DefinitionVon Willebrand disease (VWD) comprises inherited disorders of von Willebrand Factor (vWF) causing mucocutaneous bleeding, excessive bruising, and bleeding with procedures or menses.

Type 1 and Type 3Quantitative vWF deficiency (reduced amount of vWF).

Type 2Qualitative vWF defect (abnormal function of vWF).

VWD dosing considerations (plasma‑derived vWF products: Alphanate, Humate‑P, Wilate)On‑demand/perioperative: approve up to 80 IU VWF:RCo/kg IV no more frequently than once every 8 hours for up to 10 days; Routine prophylaxis: approve up to 40 IU VWF:RCo/kg IV no more frequently than once every 2 days.

OpenPayer

Hemophilia — Factor VIII Products Utilization Management Medical Policy

Recommended Authorization Criteria

Dosing and Coding Thresholds

Prescriber and Authorization Requirements

Clinical Background

Key Definitions